Glenmark Pharmaceuticals Limited has entered into an exclusive licensing agreement with Lotus Pharmaceutical Co. Ltd. to commercialize its Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray in Singapore, Hong Kong and Vietnam.
Glenmark will be responsible for the manufacture and supply of Ryaltris, while Lotus will commercialize the allergic rhinitis treatment in...








